Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.65 |
| ▸ | ERBB2 | P04626 | 16/20 | 0.65 |
| ▸ | GAK | O14976 | 1/20 | 0.62 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.60 |
| ▸ | ABL1 | P00519 | 3/20 | 0.56 |
| ▸ | INSR | P06213 | 3/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.56 |
| ▸ | CDK2 | P24941 | 3/20 | 0.56 |
| ▸ | PLK1 | P53350 | 3/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23127803 | 0.94 | ERBB2 (0.65) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL20220592 | 0.94 | ERBB2 (0.65) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL3698693 | 0.93 | EGFR (0.62) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL6959360 | 0.93 | EGFR (0.62) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL29651886 | 0.93 | EGFR (0.62) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL3698690 | 0.93 | EGFR (0.62) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL12202155 | 0.93 | EGFR (0.61) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL19121111 | 0.92 | EGFR (0.67) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL2478977 | 0.92 | EGFR (0.60) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL2478975 | 0.92 | EGFR (0.60) | EGFRERBB2GAKERBB4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953016-B2 | Solid dosage form containing quinazoline derivative | SHIONOGI & CO., LTD. (JP) | 2021-03-23 | — | — | US | disclosed |
| US-20190256506-A1 | SALTS OF QUINAZOLINE DERIVATIVE OR CRYSTALS THEREOF, AND THE PROCESS FOR PRODUCING THEREOF | SHIONOGI & CO., LTD. (JP) | 2019-08-22 | — | — | US | disclosed |
| US-10329285-B2 | Salts of quinazoline derivative or crystals thereof, and the process for producing thereof | SHIONOGI & CO., LTD. (JP) | 2019-06-25 | — | — | US | disclosed |
| US-20180215744-A1 | SALTS OF QUINAZOLINE DERIVATIVE OR CRYSTALS THEREOF, AND THE PROCESS FOR PRODUCING THEREOF | SHIONOGI & CO., LTD. (JP) | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953016-B2 | Solid dosage form containing quinazoline derivative | RAB5C, MAP1LC3C, TBC1D5 | EGFR 3987/4885ERBB2 3948/4885GAK 2067/4885 |
| US-20180215744-A1 | SALTS OF QUINAZOLINE DERIVATIVE OR CRYSTALS THEREOF, AND THE PROCESS FOR PRODUCING THEREOF | NQO2, SQLE, CYP3A5 | EGFR 3993/4885ERBB2 4104/4885GAK 1940/4885 |
| US-20190256506-A1 | SALTS OF QUINAZOLINE DERIVATIVE OR CRYSTALS THEREOF, AND THE PROCESS FOR PRODUCING THEREOF | NQO2, SQLE, CYP3A5 | EGFR 3993/4885ERBB2 4104/4885GAK 1940/4885 |
| US-10329285-B2 | Salts of quinazoline derivative or crystals thereof, and the process for producing thereof | NQO2, SQLE, CYP3A5 | EGFR 3993/4885ERBB2 4104/4885GAK 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.